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Abstract
Background Case-control studies have reported inconsistent
results concerning breast cancer risk and polymorphisms in
genes that control endogenous estrogen biosynthesis. We
report findings from the first family-based association study
examining associations between female breast cancer risk and
polymorphisms in two key estrogen-biosynthesis genes CYP17
(T→C promoter polymorphism) and CYP19  (TTTA repeat
polymorphism).
Methods We conducted the study among 278 nuclear families
containing one or more daughters with breast cancer, with a
total of 1123 family members (702 with available constitutional
DNA and questionnaire data and 421 without them). These
nuclear families were selected from breast cancer families
participating in the Metropolitan New York Registry, one of the
six centers of the National Cancer Institute's Breast Cancer
Family Registry. We used likelihood-based statistical methods
to examine allelic associations.
Results We found the CYP19 allele with 11 TTTA repeats to be
associated with breast cancer risk in these families. We also
found that maternal (but not paternal) carrier status of CYP19
alleles with 11 repeats tended to be associated with breast
cancer risk in daughters (independently of the daughters' own
genotype), suggesting a possible in utero effect of CYP19. We
found no association of a woman's breast cancer risk either with
her own or with her mother's CYP17 genotype.
Conclusion This family-based study indicates that a woman's
personal and maternal carrier status of CYP19 11 TTTA repeat
allele might be related to increased breast cancer risk. However,
because this is the first study to report an association between
CYP19 11 TTTA repeat allele and breast cancer, and because
multiple comparisons have been made, the associations should
be interpreted with caution and need confirmation in future
family-based studies.
Keywords: breast cancer, cyp17, cyp19, estrogen biosynthesis genes, family-based design
Introduction
Cumulative exposure to circulating estrogen is considered
to be of primary importance in breast cancer etiology.
Estrogen biosynthesis, cellular binding and metabolism
involve many steps, and the genes controlling these steps
may contribute to inherent variability in breast cancer sus-
ceptibility. Endogenous estrogen is produced predomi-
nantly in the ovarian theca cells in premenopausal women
and in the breast stromal adipose cells in postmenopausal
women. The present study focuses on CYP17 and CYP19,
two key genes that control the biosynthesis of estradiol and
estrones from their lipid precursors and are expressed in
these cells. CYP17 controls two successive early steps of
endogenous estrogen biosynthesis by converting pregne-
nolone and progesterone to precursors of androgen and
estrogen. CYP19, also known as aromatase, controls the
terminal step of estrogen biosynthesis by converting 19-
FGAP = Family Genetic Analysis Program; FS = founder statistic; MNYR = Metropolitan New York Registry; NFS = nonfounder statistic; PCR = 
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carbon steroids (testosterone and androstenedione) to 18-
carbon estrogens (estradiol and estrone).
A T→C single-nucleotide polymorphism in the 5' promoter
region of the CYP17 gene and a TTTA repeat polymor-
phism in the exon 4–intron 5 boundary region of the
CYP19 gene have been investigated in breast cancer by
several studies, with inconsistent results [1,2]. For both
polymorphisms the variant alleles are considered to be
related to an increased biosynthesis of endogenous estro-
gen. The CYP17 T→C polymorphism is thought to create
an Sp1-type (CCACC) promoter site (although one study
did not confirm this [3]) and is associated with an increased
serum estrogen level [4,5]. After Feigelson and colleagues
first published their study [6] showing a higher risk of
breast cancer in relation to the CYP17 C allele among non-
Caucasian women, many other authors attempted to repli-
cate this in other populations. Although some studies con-
firmed this initial finding, others did not. All studies
reporting an increased risk, including the original study,
found the increased risk in one or more certain subgroups
of women studied, for example women with advanced dis-
ease [6], women aged less than 40 years [7], women aged
less than 40 years with family history [8], women aged
more than 55 years [9], and women also carrying other
genetic polymorphisms [10]. Two studies found that
women carrying CYP17 C allele are less likely to use hor-
mone replacement therapy [5,11] and three studies found
that the protective effect of later age at menarche is
stronger among women who do not carry the C allele
[5,6,12]. A recent meta-analysis concluded that the CYP17
T→C polymorphism is not a significant independent risk
factor for breast cancer [2].
The CYP19 gene contains a variable number (range 7–13)
of TTTA repeats in the exon 4–intron 5 boundary region,
creating polymorphisms that have been examined in five
studies [13-17]. Kristensen and colleagues [13] and sub-
sequently others found a roughly twofold to fourfold ele-
vated risk in relation to certain numbers of CYP19 TTTA
repeat polymorphisms. Although one small study found a
higher risk in relation to the TTTA seven repeats allele,
(TTTA)7 [14], most studies reporting an association found
elevated risks in relation to one of the higher number of
TTTA repeat alleles: 10 repeats, (TTTA)12 [13]; 12 repeats,
(TTTA)10 [15,16]; or 10 or more repeats, (TTTA)≥10 [17]. A
meta-analysis published in 1999 based on some of the ear-
lier studies found that women carrying the CYP19 (TTTA)10
allele were at higher risk of breast cancer [1].
All published studies of association between the CYP17
and CYP19 polymorphisms and breast cancer discussed
above used a classical case-control design. A recent meta-
analysis of CYP17 T→C polymorphism indicates substan-
tial differences in genotype frequencies in case-control
studies conducted in different populations [2], with propor-
tions of carriers ranging from 0.46 in the UK [18] to 0.79 in
Japan [19] and proportions of homozygotes ranging from
11% in Finland [12] to 36% in Taiwan [10]. Similarly, the
allele frequency of the CYP19 (TTTA)10 allele ranges from
0.5% [15] to 1.8% [14]. Given that case-control studies
can be susceptible to population stratification bias, it is
important to examine these potentially important biologi-
cally plausible hypotheses in family-based studies that are
free from such bias. In this study we examine the associa-
tion between the CYP17 promoter T→C and CYP19 TTTA
repeat polymorphisms and female breast cancer by using a
family-based design among nuclear families participating in
the Metropolitan New York Registry (MNYR), one of the six
international centers of the National Cancer Institute's
Breast Cancer Family Registry project. Although other pol-
ymorphisms in the CYP17 and CYP19 genes have been
reported, we focused on these two polymorphisms
because they have been studied most extensively both in
relation to their potential associations with breast cancer
and also in relation to their influence on circulating
estrogens.
All published studies focused on the relationship between
a woman's own constitutional genotype and her breast
cancer risk. A body of recent literature has provided limited
data suggesting that a woman's breast cancer risk might
be related not only to her own endogenous estrogens dur-
ing adolescence and adulthood, but also to her prenatal
exposure; that is, her exposure in utero to her maternal cir-
culating estrogens [20-25]. In addition to the main associ-
ation between a woman's own genotype and her breast
cancer status, the family-based design of the present study
allows us to address this hypothesis indirectly, by examin-
ing the association between maternal carrier status of
CYP17 or CYP19 gene variants (that is, exposure in utero
to an altered level of maternal estrogens) and breast cancer
status in daughters.
Methods
Selection of study participants
Since 1995 the MNYR has been recruiting families with
breast and/or ovarian cancers in clinical and community
settings within the metropolitan New York area. Families
meeting one or more of the following criteria are invited to
participate: a female less than 45 years of age at diagnosis
of breast cancer; a female with both breast and ovarian
cancer; three or more relatives with breast or ovarian can-
cer diagnosed at age 45 years or more, or any male with
breast cancer. After identification of a proband he/she is
invited to participate in the registry and his/her family's eli-
gibility is assessed. If the family is eligible and the proband
agrees to participate, after appropriate informed consent,
he/she is interviewed either in person or by phone with an
epidemiology questionnaire and a family-historyAvailable online http://breast-cancer-research.com/content/7/1/R71
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questionnaire. The proband is also asked to provide per-
mission to contact family members. Blood or buccal sam-
ples are also collected and participants are provided with a
self-administered dietary questionnaire to be returned by
mail. Once family members consent to participate, data and
blood or buccal samples from the family members are also
collected in a similar manner. For members affected with
cancer, tumor tissue samples are collected and reviewed
pathologically. Genomic DNA from white blood cells or
buccal samples has been collected for participants who
donated biological samples. So far, the MNYR has enrolled
1158 families and more than 3900 total participants.
For this study we restricted attention to nuclear families
with at least one affected daughter and at least one parent
and/or sibling for whom DNA samples were available. Of
the 1158 families enrolled in the MNYR so far, 278 families
met these eligibility criteria. Subjects can participate in the
MNYR with or without completion of the full epidemiology
questionnaire and/or blood samples. There were 1123
family members in the 278 eligible nuclear families, of
whom 702 completed the full epidemiology questionnaire
and provided blood samples. However, accurate data on
relevant variables for the statistical method used in this
study (see below) for the remaining 421 members were
available from the family-history questionnaire completed
by the 702 members. There was 99% concordance in data
on age and affected status between women who com-
pleted the full epidemiology questionnaire and women who
did not.
Laboratory analysis
We evaluated association between the T→C single-nucle-
otide polymorphism in the promoter region of the CYP17
gene and the tetranucleotide (TTTA) repeat polymorphism
in the exon 4–intron 5 boundary of the CYP19 gene. A total
of 23 subjects could not be genotyped for CYP17, and 26
subjects could not be genotyped for CYP19. Genotype
data were available on a total of 679 members (from 277
nuclear families) for CYP17 and 676 members (from 278
nuclear families) for CYP19.
The CYP17 promoter polymorphism was determined with
template-directed primer extension and detection by fluo-
rescence polarization in a 96-microwell-based format
[26,27]. In brief, DNA isolated from blood cells by salting
out was used for genotyping subjects. First, the target DNA
was amplified by polymerase chain reaction (PCR; using
forward primer 5'-TTTAAAAGGCCTCCTTGTGC-3' and
reverse primer 5'-TTGGGCCAAAACAAATAAGC-3') to
generate products in the range 100–200 base pairs. After
amplification by PCR, the primers were digested with
shrimp alkaline phosphatase and Escherichia coli exonu-
clease I. Then single-nucleotide extension was performed
in the presence of the appropriate allele-specific ddNTPs
differentially fluorescence-labeled with either R110 or
tetramethylrhodamine purchased from NEN Life Sciences
(Boston, MA). For the single-nucleotide extension reaction
both forward and reverse probes were tested to select the
optimum (the forward probe 5'-GCCACAGCTCTTC-
TACTCCAC-3') on the basis of clear signal differences.
The incorporation resulted in diminished rotation of the
fluor compared with the ddNTP. Finally, the fluorescence
polarization was read on a fluorescence polarization micro-
plate reader (Tecan Polarion, Research Triangle Park, NC).
The reader generates the genotype data on the basis of the
distinct separations (with appropriate cut-offs) of the fluo-
rescent intensity values for different alleles in comparison
with internal controls.
The CYP19 TTTA repeats were determined by PCR ampli-
fication (using the forward primer 5'-GTCTATGAATGT-
GCCTTTTT-3' and the reverse primer 5'-
GTTTGACTCCGTGTGTTTGA-3') followed by analysis on
an ABI 377 system with GenScan software on the basis of
the separations on gel according to the differences in the
number of TTTA repeats.
All laboratory assays were performed with laboratory per-
sonnel blinded to the subject's disease status or family rela-
tionships. In addition to assay-specific quality-control
samples, 10% of samples were reassayed after relabeling
to keep laboratory staff blinded to its identity.
Statistical analysis
We used the Family Genetic Analysis Program (FGAP
[28], freely available at http://www.stanford.edu/dept/
HRP/epidemiology/FGAP) to test the null hypothesis of no
association between genotype and breast cancer risk in
nuclear families. The FGAP computes two test statistics:
the nonfounder statistic (NFS), a generalization of the
transmission disequilibrium test (TDT) [29,30], which eval-
uates transmission disequilibrium from parents to offspring,
and the founder statistic (FS), which compares the distribu-
tion of parental genotypes with that expected under the null
hypothesis of no association. The FGAP statistics fully
exploit data from families with variable numbers of affected/
unaffected members with variable (known/unknown) pat-
terns of parental genotypes. They are similar to, but can be
more powerful than, those available in the software FBAT
[31]. (See [32] for a comparison of the methods.)
On the basis of the previous evidence [6,13,15,17], we
hypothesized that breast cancer risk is elevated among car-
riers of the CYP17 C allele and the CYP19 variant alleles
with 10 or more TTTA repeats, namely the (TTTA)10,
(TTTA)11, (TTTA)12, and (TTTA)13 alleles. The data analysis
was focused on two specific components of the study
hypotheses: first, whether a woman's carrier status of the
hypothesized alleles is associated with her breast cancerBreast Cancer Research    Vol 7 No 1    Ahsan et al.
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status, and second, whether a mother's carrier status of the
hypothesized alleles is associated with her daughter's
breast cancer risk. For testing the first component of a
hypothesis, we applied the FS and NFS to assess whether
specific genotypes of each of the studied genes are related
to breast cancer. Because FS and NFS follow a normal
Gaussian distribution under the null hypothesis, the
assessment of statistical significance of the association
can be done on the basis of the deviation of these statistics
from the standard critical values under normal distribution.
For simplicity, we describe these analyses for the CYP17
gene as applied to nuclear families consisting of two par-
ents and at least one daughter. Parents may be untyped
and the mother's breast cancer status may be unknown.
The test statistics, which are likelihood-based score statis-
tics, are obtained by summing the score contributions from
each family. These family-specific scores are obtained in
three steps.
In the first step we imputed a probability distribution for the
genotypes of each pair of parents, conditional on the
observed genotypes of all family members. To do this, we
obtained maximum-likelihood estimates of the genotypes
TT, TC and CC for each of a pair of parents, given the
observed genotypes in the family. These estimates do not
require the assumption of Hardy–Weinberg frequencies for
parental genotypes. If, for example, both parents' geno-
types were known, then the probabilities are degenerate at
the observed genotypes. Similarly, if both parents' geno-
types were unknown but two offspring had observed
CYP17 genotypes TT and CC, then the parental distribu-
tions are degenerate at TC because both parents must be
heterozygotic.
In the second step we used the inferred parental genotype
distribution and the offspring's observed genotypes to test
whether heterozygous parents were equally likely to trans-
mit T and C alleles to affected daughters. This evaluation is
based on the NFS. Under the null hypothesis of equal trans-
mission of T and C alleles from parents to affected daugh-
ters, the NFS has an asymptotic standard Gaussian
distribution. The NFS generalizes the TDT to families with
untyped parents and to families with both affected and
unaffected daughters. It can be considerably more power-
ful than the sibling TDT test [33] when applied to families
without unaffected daughters.
In the final step we used the inferred parental genotypes
(and the mothers' breast cancer phenotypes) in the FS to
compare the parental genotype distribution with the
expected distribution under the null hypothesis of no asso-
ciation. This statistic treats the affected and unaffected
mothers like cases and controls in a case-control study.
However, each parent's contribution is weighted in propor-
tion to his/her number of affected and unaffected daugh-
ters, so that parents of many affected daughters receive
higher weights than do those of few affected daughters.
To test the second component of our hypothesis, namely
the association between maternal carrier status and daugh-
ter's breast cancer status, we evaluated whether the geno-
types of mothers with more affected daughters differ from
those of mothers with less affected daughters. Such devia-
tion might be expected if some aspect of a daughter's envi-
ronment  in utero, governed by the mother's genotype,
influences the daughter's risk of subsequent breast cancer
development. The FS was adapted to evaluate this ques-
tion by comparing the observed or imputed genotypes of
mothers of affected daughters with the genotypes
expected in the parental population. It is a weighted sum of
differences between each mother's observed (or inferred)
C allele count and the average C count in the population.
In symbols, each family's contribution to this sum is propor-
tional to the quantity (nA - nU)(Cobs - Cexp), where nA and nU
are,, respectively, the numbers of affected and unaffected
daughters in the family, and Cobs and Cexp are the observed
and expected C-allele counts for the mother. Under the null
hypothesis of no association between maternal genotype
and daughters' breast cancer risks, Cobs has a mean value
Cexp, so Cobs - Cexp = 0 in expectation for all families. Thus
the FS has expectation zero and the correct type I error rate
regardless of the actual numbers of affected and unaf-
fected daughters in each family. Under the alternative
hypothesis that maternal C-allele count is associated with
daughters' breast cancer risks, one expects that Cobs - Cexp
> 0, and thus families with many affected daughters and
few unaffected daughters (that is, nA - nU >> 0) contribute
larger values to the FS than those with few affected daugh-
ters or those with many unaffected daughters. A statistically
significant value of the FS when restricted to the mothers
(with an insignificant value when restricted to the fathers)
would provide evidence for this association.
When the null hypothesis is rejected, it is useful to estimate
a measure of association between genotype and risk, such
as the odds ratio, and to evaluate the effects of potential
confounding by hormonal factors. To do so, we also per-
formed conditional logistic regression analyses [34,35] on
all the available sibships containing at least one affected
sibling and at least one unaffected sibling who had pro-
vided blood samples and relevant epidemiology data for
statistical adjustment (165 sibships for CYP17 and 169
sibships for CYP19).
Results
Of the 277 nuclear families eligible for CYP17 analyses,
229 were Caucasian, 4 were African American, 41 were
Hispanic, and 3 were Asian American. Of the 278 nuclear
families eligible for CYP19 analyses, 229 were Caucasian,Available online http://breast-cancer-research.com/content/7/1/R71
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4 were African American, 42 were Hispanic, and 3 were
Asian American. Table 1 shows the distribution of the study
subjects according to CYP17 and CYP19 genotypes, by
family position and breast cancer status. The numbers in
each cell represent the number of specific type of family
members in our study population carrying a particular gen-
otype. The number of TTTA repeats in intron 4 of the
CYP19 gene ranged between 7 and 13 in our study popu-
lation, with the (TTTA)7 and (TTTA)11 alleles being the most
frequent (allele frequencies 53.9% and 28.8%, respec-
tively). These frequencies are consistent with those found
in Caucasian populations in other studies in the USA [15].
The frequency of the CYP17 variant C allele was 42.8% in
this study population, which is similar to that found in other
studies conducted in Caucasians [4].
The distribution of the nuclear families according to
mother's and father's carrier status and mother's and
daughter's affected status is presented in Table 2. A major-
ity (about 55%) of the nuclear families contained one
Table 1
Genotype distribution of the study population by gender, family relationship and affected status
Mothers Daughters
Genotype Affected Unaffected Affected Unaffected Fathers Sons Total
CYP17
C C 2 1 04 74 1 6 1 1 1 1 7
CT 8 32 147 108 30 22 347
T T 21 9 1 0 7 6 181 8 2 1 5
Unknown 64 140 0 0 233 0 437
Total 76 201 301 210 277 51 1116
CYP19 (no. of TTTA repeats)
7/7 1 15 88 55 7 21 187
7/8 0 10 34 29 4 5 82
7 / 9 0010102
7 / 1 0 015620 1 4
7/11 9 19 106 71 14 19 238
7 / 1 2 029800 1 9
7 / 1 3 0000101
8 / 8 0041005
8 / 1 0 0132006
8/11 1 2 24 16 1 3 47
8 / 1 2 0012003
8 / 1 3 0001001
9 / 1 1 0001001
1 0 / 1 1 0023027
11/11 0 5 19 16 1 1 42
1 1 / 1 2 0142007
1 1 / 1 3 1021105
11/not 11a 1300509
Unknown 63 143 0 0 241 0 447
Total 76 202 302 214 278 51 1123
aIndicates those whose genotype cannot be inferred for both alleles; the other allele could be 7, 8, or 12. Two of these nine observations, one an 
unaffected mother and the other the father in the same nuclear family, will be excluded when the allele with 10 or more repeats is selected as bad 
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affected and one unaffected daughter. The majority of the
nuclear families had one or more parents who did not have
the genotyping information available.
Table 3 presents the FS and NFS for testing the associa-
tions between the a priori hypothesized  CYP17  and
CYP19 variant alleles and breast cancer. Each test statistic
has an approximately standard Gaussian distribution under
the null hypothesis of no association between genotype
and breast cancer risk. A positive value of a NFS reflects
excess transmission of the variant allele to affected daugh-
ters, and a negative value represents fewer such transmis-
sions than expected under the null. Thus a test statistic that
is negative but large in absolute value would suggest that
the variant allele is associated with reduced risk. We com-
puted the FS and NFS under recessive, dominant, and
additive models. For the dominant models, the number of
affected daughters carrying one or more copies of the var-
iant alleles was compared with that expected from the
parental genotypes in accordance with Mendelian expecta-
Table 2
Distribution of participating nuclear families according to mother's breast cancer status, mother's and father's carrier status of the 
CYP17 and CYP19 variant alleles, and number of affected and unaffected daughters
Number of nuclear families according to mother's breast cancer status and 
genotype
Number of nuclear families according to father's 
genotype
Number of daughters 
affected/unaffected
Affected Unaffected Total Total
Carrier Non-carrier Unknown Carrier Non-carrier Unknown Carrier Non-carrier Unknown
CYP17
1/0 3 0 19 17 12 29 80 12 2 66 80
1/1 5 2 38 16 6 85 152 19 4 129 152
1 / 2 00240 1 4 2 0 42 1 4 2 0
1 / 3 00120030033
2 / 0 203119 1 6 00 1 6 1 6
2 / 1 00000220022
2 + / 2 + 00120141034
Total 10 2 64 42 19 140 277 36 8 233 277
CYP19 > = 10 repeats
1/0 4 0 17 14 13 29 77 7 4 66 77
1/1 5 1 40 12 9 88 155 10 6 139 155
1 / 2 10151 1 4 2 2 52 1 5 2 2
1 / 3 10010021012
2 / 0 104119 1 6 10 1 5 1 6
2 / 1 00000220022
2 + / 2 + 00101240044
Total 12 1 63 33 25 144 278 24 12 242 278
CYP19 = 11 repeats
1/0 4 0 17 11 16 29 77 6 5 66 77
1/1 5 1 40 11 10 88 155 9 7 139 155
1 / 2 10161 1 3 2 2 53 1 4 2 2
1 / 3 10010021012
2 / 0 104119 1 6 10 1 5 1 6
2 / 1 00000220022
2 + / 2 + 00101240044
Total 12 1 63 30 29 143 278 22 15 241 278Available online http://breast-cancer-research.com/content/7/1/R71
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tion. Similarly, for the recessive models, the number of
affected daughters homozygous for the variant allele was
compared with that expected under Mendelian expectation.
For the additive models, the total variant allele count in
affected daughters was compared with that expected from
the parental genotypes in accordance with Mendelian
expectation. On the basis of the literature, we hypothesized
a priori that CYP19 alleles with 10 or more TTTA repeats
would be associated with breast cancer. In addition, we
examined the association between the CYP19 genotype
and breast cancer by defining the variant allele(s) by treat-
ing each of the 10 or more repeat alleles, (TTTA)10,
(TTTA)11, (TTTA)12 and (TTTA)13, separately as the variant
allele under each of the three models (realizing that this
might have increased the chance of our finding of a statis-
tically significant association; see the Discussion section).
As seen in Table 3, the NFS for association between the
(TTTA)11  allele and breast cancer under the dominant
model is 1.83, which is higher than the critical value (1.65)
for a one-tailed test statistic, suggesting that affected
daughters were more likely to receive the (TTTA)11 allele
from their parents (irrespective of their ethnic distribution)
than unaffected daughters. Like the NFS, the FS was also
statistically significant under the dominant model, support-
ing an association between the CYP19 (TTTA)11 allele and
breast cancer among the parents in these families. The
results for CYP19 TTTA≥10 alleles did not show a consist-
ent association, because only the FS was statistically sig-
nificant under the dominant model. None of the other
specific CYP19 alleles showed a consistent association
with breast cancer on the basis of the NFS and FS (results
not shown). Although the FS found an association between
the CYP19 (TTTA)13 allele and breast cancer, this was not
supported by the more robust NFS (results not shown).
Neither the FS nor the NFS suggested any significant asso-
ciation between the CYP17 variant C allele and breast can-
cer, under any of the models of FGAP analyses (see Table
3).
Table 4 presents the results of conditional logistic regres-
sion analysis comparing the CYP17  and  CYP19  geno-
types between affected and unaffected sisters. These
results, adjusted for age (in years), hormone replacement
use (ever/never), oral contraceptive use (ever/never), age
at menarche (in years) and term pregnancies (yes/no), are
similar to the FGAP results although because of the smaller
number of available sibships the associations did not
achieve statistical significance. As seen in Table 4, carriers
of the CYP19  (TTTA)11 allele had an increased risk of
breast cancer (odds ratio 1.8; 95% confidence interval
0.9–3.5).
Table 5 presents results relating maternal and paternal car-
rier statuses for the variants of estrogen-biosynthesis
genes CYP17 and CYP19 to breast cancer risk in daugh-
ters. Mothers of affected daughters were more likely to
carry the CYP19  (TTTA)11  allele than expected in the
parental population. There were no such associations
between the paternal carrier status of (TTTA)11 and any of
the other CYP19 alleles and breast cancer in daughters.
For this hypothesis, the findings for analysis involving
CYP19  (TTTA)≥10 corroborated that for (TTTA)11 alleles.
Although maternal carrier status of the CYP17  C allele
tended to be positively associated with daughter's breast
cancer, this association was not specific to the mothers but
was also present among the fathers.
Discussion
Despite a sound biological basis for the role of estrogen-
biosynthesis genes in breast cancer, the findings of studies
investigating the relationship between these genes and
Table 3
Association between the CYP19 and CYP17 variant alleles and breast cancer
Nonfounder statistic Founder statistic
Variant allele(s) Estimated allele 
frequency (%)
Recessive model Dominant model Additive model Recessive model Dominant model Additive model
CYP17
C 42.46 - 1.01 - 1.52 - 1.85 0.40 1.08 1.01
P 0.16 0.06 0.03 0.34 0.14 0.16
CYP19
(TTTA)≥10 33.71 - 1.24 1.26 0.32 - 0.32 1.66 1.13
P 0.11 0.10 0.38 0.37 0.05 0.13
(TTTA)11 28.78 - 1.09 1.83 0.97 - 1.50 1.96 0.89
P 0.14 0.03 0.17 0.07 0.03 0.19
P values are based on one-tailed test statistics. Values that are statistically significant at one-tailed test are displayed in bold type.Breast Cancer Research    Vol 7 No 1    Ahsan et al.
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breast cancer have not been consistent. Employing a case-
control design, many of these prior studies, especially
those examining the CYP17 gene–breast cancer relation-
ships, produced conflicting results. Although in compari-
son with CYP17 a smaller number of studies investigated
the association of breast cancer with CYP19, findings for
CYP19  have been more consistent, with most studies
showing a positive association between CYP19  alleles
with a higher number (10, 12, or 10 or more) of TTTA
repeats and breast cancer [13,15-17].
Using a family-based design we investigated the relation-
ships between the CYP17 and CYP19 gene variants and
breast cancer in families participating in the MNYR. Like
many of the previous case-control studies, the present
study did not find any association between the CYP17 C
(variant) allele and breast cancer. However, our findings
support an association between certain alleles of the
CYP19  intron 4 TTTA repeat polymorphism and breast
cancer. On the basis of the previous studies we defined
each of the CYP19 alleles with 10, 11, 12, or 13 TTTA
repeats as the 'variant' allele and examined each associa-
Table 4
Conditional logistic regression analysis of discordant sibships for the association between CYP17 and CYP19 genotypes and breast 
cancer
Gene (sibling sets/cases/controls) Affected (n) Unaffected (n) Adjusted odds ratios for 
breast cancer (95% CI)
CYP17 (165/171/188)
Dominant model TT 59 56 1.00
TC/CC 112 132 0.86 (0.47–1.59)
Recessive model TC/TT 146 154 1.00
CC 25 34 0.61 (0.27–1.41)
General model TT 59 56 1.00
TC 87 98 0.86 (0.47–1.59)
CC 25 34 0.55 (0.21–1.42)
Additive model (trend per allele) 0.77 (0.49–1.21)
CYP19 (no. of TTTA repeats) (169/175/193)
Dominant model (TTTA)<10(TTTA)<10 67 78 1.00
(TTTA)≥10(TTTA)<10/(TTTA)≥10(TTTA)≥10 108 115 1.24 (0.63–2.46)
Recessive model (TTTA)<10(TTTA)<10/(TTTA)≥10(TTTA)<10 159 173 1.00
(TTTA)≥10(TTTA)≥10 16 20 0.82 (0.30–2.24)
General model (TTTA)<10(TTTA)<10 67 78 1.00
(TTTA)≥10(TTTA)<10 92 95 1.26 (0.64–2.51)
(TTTA)≥10(TTTA)≥10 16 20 0.98 (0.30–3.18)
Additive model (trend per allele) 1.11 (0.65–1.89)
Dominant model (TTTA)other(TTTA)other 77 95 1.00
(TTTA)11(TTTA)other/(TTTA)11(TTTA)11 98 98 1.77 (0.90–3.47)
Recessive model (TTTA)other(TTTA)other/(TTTA)11(TTTA)other 165 179 1.00
(TTTA)11(TTTA)11 10 14 0.66 (0.19–2.33)
General model (TTTA)other(TTTA)other 77 95 1.00
(TTTA)11(TTTA)other 88 84 1.84 (0.93–3.63)
(TTTA)11(TTTA)11 10 14 1.04 (0.27–4.08)
Additive model (trend per allele) 1.38 (0.79–2.40)
Odds ratios were adjusted for age (in years), hormone replacement use (ever/never), oral contraceptive use (ever/never), age at menarche (in 
years), full term pregnancies (yes/no). Each sibling set had at least one breast cancer case and one sister control. All the subjects included in the 
analysis had information for all the covariate variables. CI, confidence interval.Available online http://breast-cancer-research.com/content/7/1/R71
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tion with breast cancer. Unlike some of the previous case-
control studies we did not find the CYP19  (TTTA)10 or
(TTTA)12 alleles to be associated with breast cancer. How-
ever, we found the CYP19 (TTTA)11 allele to be signifi-
cantly associated with breast cancer in these nuclear
families, under a dominant model. Although we also
observed a significantly positive association between the
CYP19 (TTTA)13 allele and breast cancer among the par-
ents in these families, we did not observe excess transmis-
sion from parents to affected daughters, suggesting that
the association might be due to chance or bias. The evi-
dence of an increased risk in relation to the CYP19
(TTTA)11 allele was also observed in the conditional logistic
regression analysis adjusting for potential confounding var-
iables among the subset of families containing discordant
sibships. However, because of the reduced power of these
analyses among only a subset of families [36], results of
these discordant sibship analyses did not achieve statisti-
cal significance.
In addition to evaluating associations between a woman's
breast cancer risk and her own constitutional genotype, we
also evaluated whether maternal genotypes are associated
with the breast cancer risk in the daughters (independent
of the daughter's own genotype). We found that the mater-
nal (but not the paternal) genotypes of the CYP19 (TTTA)11
allele conferred a non-significantly elevated breast cancer
risk to daughters. This effect was also observed when all
(TTTA)≥10 alleles were treated as the variant allele. This
association is consistent with evidence from the previous
literature on the association between exposure to hormonal
factors in utero and breast cancer risk in adulthood [20].
Although the association might be due to chance, if con-
firmed in subsequent studies it will have important implica-
tions in advancing our understanding of the breast cancer
etiology.
Some limitations of the present study merit consideration.
The major limitation concerns statistical power. The analy-
sis, which is based on 287 nuclear families, might not have
had enough power to detect small increases in risk associ-
ated with certain of the CYP17 genotypes. For example, we
lacked power to evaluate interactions between genotypes
for CYP17 and CYP19 and both endogenous and exoge-
nous hormonal characteristics, such as age at menarche,
timing and number of pregnancies and the use of exoge-
nous hormones. In addition, although there is evidence for
variations in the allele frequencies of the studied polymor-
phisms across ethnic groups, we lacked statistical power
to conduct ethnicity-specific analyses. The evaluation of
such analyses will be the subject of a separate future anal-
ysis, based on additional numbers of Breast Cancer Family
Registry families.
Although the hypotheses examined in this study are not
novel, the study design (which is free from population strat-
ification bias) and the analytical approach have not been
applied to these hypotheses in previous studies. Several
limitations of this study require caution when interpreting
the findings. First, the selection of nuclear families partici-
pating in this study from the MNYR was not population-
based. Although this might limit the generalizability of the
findings it should not affect the validity of the observed
associations. Second, although it is possible for variations
in the number of nucleotide repeats in hormone-related
genes to be associated with cancer risk, such an associa-
tion is less plausible biologically for the TTTA repeat num-
bers in the CYP19  gene. This is because the TTTA
polymorphism is in the intronic region of the gene and so it
Table 5
Association between parental carrier status of the variant allele(s) and breast cancer risk in daughters
Test statistic
Mothers' carrier status and disease risk in daughters Fathers' carrier status and disease risk in daughters
Variant allele(s) Additive Dominant Additive Dominant
CYP17
C 1.47 1.09 1.40 1.07
P 0.07 0.14 0.08 0.14
CYP19
(TTTA)≥10 1.73 1.65 0.95 0.45
P 0.04 0.05 0.17 0.33
(TTTA)11 1.52 1.96 - 0.11 0.18
P 0.06 0.03 0.46 0.43
The test statistic was calculated under the additive model. P values are based on one-tailed test statistics.Breast Cancer Research    Vol 7 No 1    Ahsan et al.
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is less likely that the variant alleles of the gene are directly
associated with the functional status of endogenous estro-
gens in the body. Nevertheless, it is possible that one or
more of the CYP19 TTTA alleles, including the (TTTA)11
allele, are in linkage disequilibrium with other functionally
relevant alleles, as suggested by other studies [16]. Third,
the present study compared multiple CYP19 TTTA alleles
with breast cancer under different models. Although it is
possible that multiple comparisons might have led to the
observed associations, the consistency of the associations
involving the CYP19 (TTTA)11 allele across both parents
and transmission to offspring as well as the similarity
between the associations with both constitutional and
maternal genotypes suggest that these findings might have
a biological basis. Further, the fact that the association was
observed under specific susceptibility models and was
consistent with conditional logistic regression analysis
might be suggestive of the specificity of the finding.
Conclusion
This family-based study found that the CYP19 (TTTA)11
allele is associated with breast cancer risk among families
participating in a breast cancer family registry. The study
also suggests that maternal carrier status of the CYP19
(TTTA)11 allele might be associated with breast cancer in
daughters in these families. These associations might have
important implications for understanding the etiology and
risk prediction of breast cancer. However, because this is
the first study to report an association with the CYP19
(TTTA)11 allele, and because multiple comparisons have
been made, the associations reported in this study should
be interpreted with caution and need to be confirmed in
future family-based studies.
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